Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 02, 2015 2:24 PM ET


Company Overview of Vaccinex, Inc.

Company Overview

Vaccinex, Inc., a biotechnology company, engages in the discovery and development of human monoclonal antibodies. The company focuses on developing antibody treatments relevant to cancer, inflammation, and auto-immune diseases, as well as products for the treatment of oncology, multiple sclerosis oncology, hematological, breast cancer, and infectious diseases. Its ACTIVMAb antibody discovery technology enables the development of therapeutic antibodies, as well as provides fee-based antibody discovery and research services for client companies; and VX15/2503 humanized monoclonal antibody targets the multi-functional protein semaphorin 4D in patients with multiple sclerosis. The company was fo...

1895 Mount Hope Avenue

Rochester, NY 14620

United States

Founded in 1997





Key Executives for Vaccinex, Inc.

Co-Founder, Chief Executive Officer, President and Director
Chief Financial Officer
Chief Operating Officer and Senior Vice President
Chief Scientific Officer and Senior Vice President of Research
Senior Vice President of Development
Compensation as of Fiscal Year 2015.

Vaccinex, Inc. Key Developments

Vaccinex, Inc. Announces the Initiation of Phase 2 Clinical Trial of its Investigational VX15/2503 Antibody in Huntington's Disease

Vaccinex, Inc. announced that it has initiated a Phase 2 clinical trial to assess the safety, tolerability and efficacy of anti-semaphorin 4D antibody VX15/2503 (VX15) in Huntington's disease (HD), a neurodegenerative genetic disorder that typically manifests in mid-adult life. This clinical trial, termed the 'SIGNAL' clinical trial, will be performed with the assistance of the Huntington Study Group and is designed to evaluate VX15 antibody in up to 84 subjects with late-prodromal or early-manifest HD. The SIGNAL trial is based on prior research of neurodegenerative disease mechanisms, where demonstrated in preclinical models that semaphorin 4D ("SEMA4D") triggers activation of both microglia and astrocytes, the innate inflammatory cells of the central nervous system. The chronic activation of microglia and astrocytes has been implicated as a potentially important disease mechanism in HD, progressive multiple sclerosis and other neurodegenerative disorders. VX15 antibody is designed to block the functional activity of SEMA4D. The SIGNAL clinical trial will build upon preclinical studies in an animal model of HD and safety data from a Phase 1 dose-escalation clinical trial of VX15 in MS patients that the company completed in November 2014.

Vaccinex, Inc. Presents at 10th Annual Neurotech Investing & Partnering Conference, Apr-08-2015 01:30 PM

Vaccinex, Inc. Presents at 10th Annual Neurotech Investing & Partnering Conference, Apr-08-2015 01:30 PM. Venue: Hotel Nikko, 222 Mason Street, San Francisco, California, United States. Speakers: Maurice Zauderer, Co-Founder, Chief Executive Officer, President and Director.

Vaccinex, Inc. Provides an Update on its VX15/2503 Phase 1 Clinical Trial in Multiple Sclerosis Patients

Vaccinex, Inc. announced the successful completion of a multicenter phase 1, randomized, double-blind, placebo-controlled, single ascending-dose safety and tolerability study in adult patients with Multiple Sclerosis. A total of 50 patients were enrolled in 1 of 5 cohorts to determine the safety and tolerability of VX15/2503 when administered IV in a single dose. VX15/2503 is a monoclonal antibody discovered, characterized, and successfully tested by Vaccinex in preclinical models of Multiple Sclerosis and Huntington's Disease. VX15/2503 was found to be well tolerated at dose levels of up to 20 mg/kg with no reports of treatment-related serious adverse events. No maximum tolerated dose was determined and no dose-limiting toxicities were observed. Preliminary data suggests that the half-life of a single dose of antibody is 21 to 23 days at the 20 mg/kg dose level, and that saturation of the SEMA4D target receptor lasted for approximately 155 days. A phase 2 clinical trial of the VX15/2503 antibody in Huntington's Disease is planned to begin in the first half of 2015.

Similar Private Companies By Industry

Company Name Region
Ansun Biopharma, Inc. United States
Colloral LLC United States
Janus Pharmaceuticals, Inc. United States
Akashi Therapeutics, Inc. United States
Merial Limited United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Vaccinex, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at